MSF Access
@msfaccess.org
Today is World Diabetes Day.
More than 800 million people have diabetes, most of whom live in low- and middle-income countries.
For people w/ type 1 diabetes, insulin is lifesaving, but it's often unavailable in low-resource and emergency settings and unaffordable elsewhere.
More than 800 million people have diabetes, most of whom live in low- and middle-income countries.
For people w/ type 1 diabetes, insulin is lifesaving, but it's often unavailable in low-resource and emergency settings and unaffordable elsewhere.
November 14, 2025 at 11:14 AM
Today is World Diabetes Day.
More than 800 million people have diabetes, most of whom live in low- and middle-income countries.
For people w/ type 1 diabetes, insulin is lifesaving, but it's often unavailable in low-resource and emergency settings and unaffordable elsewhere.
More than 800 million people have diabetes, most of whom live in low- and middle-income countries.
For people w/ type 1 diabetes, insulin is lifesaving, but it's often unavailable in low-resource and emergency settings and unaffordable elsewhere.
Lecritia, from South Africa, is comfortable using insulin pens.
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
November 14, 2025 at 11:08 AM
Lecritia, from South Africa, is comfortable using insulin pens.
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
Scientists discovered insulin over 100 years ago, envisioning a world where everyone could access #diabetes treatment.
But it is often unavailable or unaffordable.
Ahead of World Diabetes Day tomorrow, we’re calling for affordable & available insulin pens for all.
But it is often unavailable or unaffordable.
Ahead of World Diabetes Day tomorrow, we’re calling for affordable & available insulin pens for all.
November 13, 2025 at 6:16 PM
Scientists discovered insulin over 100 years ago, envisioning a world where everyone could access #diabetes treatment.
But it is often unavailable or unaffordable.
Ahead of World Diabetes Day tomorrow, we’re calling for affordable & available insulin pens for all.
But it is often unavailable or unaffordable.
Ahead of World Diabetes Day tomorrow, we’re calling for affordable & available insulin pens for all.
Today @who.int released their 2025 #tuberculosis report, and figures remain unacceptable: 1.2 million children and young adolescents fell ill in 2024, and a staggering 43% were never diagnosed and thus missed lifesaving treatment. Act now to close the deadly gap!
msfaccess.org/msf-responds...
msfaccess.org/msf-responds...
November 12, 2025 at 3:22 PM
Today @who.int released their 2025 #tuberculosis report, and figures remain unacceptable: 1.2 million children and young adolescents fell ill in 2024, and a staggering 43% were never diagnosed and thus missed lifesaving treatment. Act now to close the deadly gap!
msfaccess.org/msf-responds...
msfaccess.org/msf-responds...
Every child withTB deserves a healthy childhood. Yet in 2023, 1.25M fell ill with TB and nearly half were never diagnosed, thus never treated.
Join our webinar moderated by @johngreensbluesky.bsky.social where survivors and treatment providers will discuss how to close these deadly gaps.
Join our webinar moderated by @johngreensbluesky.bsky.social where survivors and treatment providers will discuss how to close these deadly gaps.
October 27, 2025 at 3:24 PM
Every child withTB deserves a healthy childhood. Yet in 2023, 1.25M fell ill with TB and nearly half were never diagnosed, thus never treated.
Join our webinar moderated by @johngreensbluesky.bsky.social where survivors and treatment providers will discuss how to close these deadly gaps.
Join our webinar moderated by @johngreensbluesky.bsky.social where survivors and treatment providers will discuss how to close these deadly gaps.
🦠 It's estimated that by 2050, antibiotic resistance will cause 8.22 million deaths per year.
To try and combat this, MSF launched Antibiogo, a free diagnostic aid app to combat antibiotic resistance by improving access to patient diagnoses.
Learn more:
To try and combat this, MSF launched Antibiogo, a free diagnostic aid app to combat antibiotic resistance by improving access to patient diagnoses.
Learn more:
October 24, 2025 at 4:03 PM
🦠 It's estimated that by 2050, antibiotic resistance will cause 8.22 million deaths per year.
To try and combat this, MSF launched Antibiogo, a free diagnostic aid app to combat antibiotic resistance by improving access to patient diagnoses.
Learn more:
To try and combat this, MSF launched Antibiogo, a free diagnostic aid app to combat antibiotic resistance by improving access to patient diagnoses.
Learn more:
➡️ @saludporderecho.bsky.social reports that in Spain the public price of WHO recommended six-month treatment BPaLM regimen is priced at €58,000. In contrast, LMICs can access the same regimen for less than €250.
saludporderecho.org/en/monopolie...
saludporderecho.org/en/monopolie...
October 23, 2025 at 2:21 PM
➡️ @saludporderecho.bsky.social reports that in Spain the public price of WHO recommended six-month treatment BPaLM regimen is priced at €58,000. In contrast, LMICs can access the same regimen for less than €250.
saludporderecho.org/en/monopolie...
saludporderecho.org/en/monopolie...
Olga*, a person living with DR-TB in Warsaw, was started on the all-oral, six-month DR-TB regimen as recommended by the WHO to replace the previous DR-TB treatment regimen which was less effective and more toxic.
October 15, 2025 at 1:20 PM
Olga*, a person living with DR-TB in Warsaw, was started on the all-oral, six-month DR-TB regimen as recommended by the WHO to replace the previous DR-TB treatment regimen which was less effective and more toxic.
At a panel discussion yesterday in Brussels, we urged policymakers, parliamentarians, regulatory agencies, and procurement bodies in the EU and the EEA to take urgent steps to bridge the gap in accessing tuberculosis treatment in the region.
msfaccess.org/msf-urges-eu...
msfaccess.org/msf-urges-eu...
October 15, 2025 at 1:15 PM
At a panel discussion yesterday in Brussels, we urged policymakers, parliamentarians, regulatory agencies, and procurement bodies in the EU and the EEA to take urgent steps to bridge the gap in accessing tuberculosis treatment in the region.
msfaccess.org/msf-urges-eu...
msfaccess.org/msf-urges-eu...
⏰ Tomorrow! Don’t miss our panel on improving access to TB medicines in EU/EEA. People with TB still face barriers to effective treatment & prevention, let's discuss solutions.
Register Now👉 us06web.zoom.us/webinar/regi...
Register Now👉 us06web.zoom.us/webinar/regi...
October 13, 2025 at 1:29 PM
⏰ Tomorrow! Don’t miss our panel on improving access to TB medicines in EU/EEA. People with TB still face barriers to effective treatment & prevention, let's discuss solutions.
Register Now👉 us06web.zoom.us/webinar/regi...
Register Now👉 us06web.zoom.us/webinar/regi...
People with TB in EU and EEA still face limited access to effective treatment and prevention medicines. How can we fix that? On 14 Oct, join our panel discussion on how to improve the availability and affordability of TB medicines in the region.
Register us06web.zoom.us/webinar/regi...
Register us06web.zoom.us/webinar/regi...
October 8, 2025 at 1:59 PM
People with TB in EU and EEA still face limited access to effective treatment and prevention medicines. How can we fix that? On 14 Oct, join our panel discussion on how to improve the availability and affordability of TB medicines in the region.
Register us06web.zoom.us/webinar/regi...
Register us06web.zoom.us/webinar/regi...
More than 800 million people have diabetes, the majority of whom live in low- and middle-income countries.
For people with type 1 diabetes, insulin is lifesaving, but it is often unavailable in low-resource and emergency settings, and unaffordable elsewhere.
For people with type 1 diabetes, insulin is lifesaving, but it is often unavailable in low-resource and emergency settings, and unaffordable elsewhere.
September 24, 2025 at 8:58 AM
More than 800 million people have diabetes, the majority of whom live in low- and middle-income countries.
For people with type 1 diabetes, insulin is lifesaving, but it is often unavailable in low-resource and emergency settings, and unaffordable elsewhere.
For people with type 1 diabetes, insulin is lifesaving, but it is often unavailable in low-resource and emergency settings, and unaffordable elsewhere.
Fleeing home while managing #diabetes can mean losing reliable access to insulin which, in turn, risks severe health consequences, even death.
Ghassan undertook a long, difficult journey with a limited supply of insulin.
How did he manage his treatment?
🧵
Ghassan undertook a long, difficult journey with a limited supply of insulin.
How did he manage his treatment?
🧵
September 22, 2025 at 8:56 AM
Fleeing home while managing #diabetes can mean losing reliable access to insulin which, in turn, risks severe health consequences, even death.
Ghassan undertook a long, difficult journey with a limited supply of insulin.
How did he manage his treatment?
🧵
Ghassan undertook a long, difficult journey with a limited supply of insulin.
How did he manage his treatment?
🧵
Sana was using continuous glucose monitoring (CGM) to monitor her blood sugar levels independently and discreetly.
However, war disrupted her access to free CGMs, so she switched to finger-prick devices which she's less comfortable with. As a result, Sana monitors less often.
However, war disrupted her access to free CGMs, so she switched to finger-prick devices which she's less comfortable with. As a result, Sana monitors less often.
September 18, 2025 at 2:43 PM
Sana was using continuous glucose monitoring (CGM) to monitor her blood sugar levels independently and discreetly.
However, war disrupted her access to free CGMs, so she switched to finger-prick devices which she's less comfortable with. As a result, Sana monitors less often.
However, war disrupted her access to free CGMs, so she switched to finger-prick devices which she's less comfortable with. As a result, Sana monitors less often.
“The main fear is just having those vials break.”
Lecritia, from South Africa, is comfortable using insulin pens.
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
Lecritia, from South Africa, is comfortable using insulin pens.
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
September 17, 2025 at 3:13 PM
“The main fear is just having those vials break.”
Lecritia, from South Africa, is comfortable using insulin pens.
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
Lecritia, from South Africa, is comfortable using insulin pens.
She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).
In 2024, only 16% of children in the Central African Republic had completed their full vaccination schedule, while 34% had never received any vaccine.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
September 12, 2025 at 4:23 PM
In 2024, only 16% of children in the Central African Republic had completed their full vaccination schedule, while 34% had never received any vaccine.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
In 2024, only 16% of children in the Central African Republic had completed their full vaccination schedule, while 34% had never received any vaccine.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
September 12, 2025 at 4:21 PM
In 2024, only 16% of children in the Central African Republic had completed their full vaccination schedule, while 34% had never received any vaccine.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
In Batangafo health zone, we work with the Ministry of Health to close this gap, providing children with routine vaccinations.
Join us for a hybrid event at Tokyo International Conference on African Development #TICAD9 where we will discuss challenges & solutions for accessing diagnostics in Africa, feature MSF field innovations and explore collaborations with Japan.
Register at www.msf.or.jp/event/detail...
Register at www.msf.or.jp/event/detail...
August 13, 2025 at 1:14 PM
Join us for a hybrid event at Tokyo International Conference on African Development #TICAD9 where we will discuss challenges & solutions for accessing diagnostics in Africa, feature MSF field innovations and explore collaborations with Japan.
Register at www.msf.or.jp/event/detail...
Register at www.msf.or.jp/event/detail...
Lenacapavir has been recommended by @who.int for HIV prevention this week. While this prevention medicine could be a game-changer in turning the tide on HIV epidemic, Gilead's licensing agreement will undermine broad access.
Here's why 👇
Here's why 👇
![“Gilead is paying lip service to equity and access while imposing restrictions on potential generic producers that will minimise scale-up of this game-changing [lenacapavir] drug while protecting and maximising its profits”, said Tom Ellman, Director of MSF Southern Africa Medical Unit.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:6vdu5tyfe5uprkloacu5pn6h/bafkreicd3n2c67ttucuirkreilcc2irj55v5qrah3qureygmshcotamyca@jpeg)
July 18, 2025 at 3:41 PM
Lenacapavir has been recommended by @who.int for HIV prevention this week. While this prevention medicine could be a game-changer in turning the tide on HIV epidemic, Gilead's licensing agreement will undermine broad access.
Here's why 👇
Here's why 👇
Insulin pens must be affordable and available for all people with #diabetes who need them.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
June 13, 2025 at 1:50 PM
Insulin pens must be affordable and available for all people with #diabetes who need them.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
Hey @novonordisk.bsky.social, all #insulin pens must be available at $1 per pen, so that everyone can access the highest standard of diabetes treatment, especially as their cost of production is estimated to be as low as $0.94 per pen, including a profit.
June 12, 2025 at 3:39 PM
Hey @novonordisk.bsky.social, all #insulin pens must be available at $1 per pen, so that everyone can access the highest standard of diabetes treatment, especially as their cost of production is estimated to be as low as $0.94 per pen, including a profit.
As per @treatmentactiongroup.org and MSF’s analysis, TB trials that are at risk include new drugs and shorter, safer regimens for treatment and prevention, an optimised regimen for TB meningitis, and therapeutic and preventive vaccines.
May 15, 2025 at 3:20 PM
As per @treatmentactiongroup.org and MSF’s analysis, TB trials that are at risk include new drugs and shorter, safer regimens for treatment and prevention, an optimised regimen for TB meningitis, and therapeutic and preventive vaccines.
Cutting support to sites in South Africa that are part of international clinical trial networks could derail up to 30% of global TB trial enrollment and between 50-90 % for studies focused on pediatric and pregnant populations.
May 15, 2025 at 3:20 PM
Cutting support to sites in South Africa that are part of international clinical trial networks could derail up to 30% of global TB trial enrollment and between 50-90 % for studies focused on pediatric and pregnant populations.